HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversible sensorineural hearing loss with intravenous erythromycin lactobionate.

Abstract
Three patients are presented who developed reversible sensorineural hearing losses during treatment with intravenous erythromycin lactobionate. A fourth patient treated with erythromycin gluceptate did not develop hearing loss. Ototoxicity with erythromycin lactobionate has been previously reported in only three patients, one of whom had medication orally. Withdrawal of the antibiotic resulted in prompt improvement in every case with return of hearing to pretreatment levels.
AuthorsC S Karmody, L Weinstein
JournalThe Annals of otology, rhinology, and laryngology (Ann Otol Rhinol Laryngol) 1977 Jan-Feb Vol. 86 Issue 1 Pt 1 Pg. 9-11 ISSN: 0003-4894 [Print] United States
PMID835977 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Erythromycin
Topics
  • Adult
  • Deafness (chemically induced)
  • Erythromycin (administration & dosage, adverse effects, analogs & derivatives)
  • Female
  • Humans
  • Injections, Intravenous
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: